CanSino Biologics Inc. (CanSinoBIO, SHSE: 688185, HKEX:06185) is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting-edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide. Since its establishment in Tianjin, China in 2009, CanSinoBIO has experienced tremendous growth with 17 vaccines preventing 12 diseases, including approved vaccines for Ebola virus disease (Ad5-EBOV), COVID-19 (Ad5-nCoV, trade name: Convidecia), and meningitis (MCV2, trade name: Menphecia). CanSinoBIO has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) in March 2019. A year later, CanSinoBIO has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+H" dual listing vaccine company. CanSinoBIO is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates. Leveraging broad experiences of our accomplished team of scientists and business leaders who had previously held technical and senior management positions at many of the leading pharmaceutical companies in the world, including Sanofi Pasteur, Astra Zeneca, Wyeth (now Pfizer) and CNBG (China), CanSinoBIO has developed five key platform technologies, including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant technology, mRNA technology as well as formulation and delivery technology.
We're tracking CanSino Biologics Inc.康希诺生物's market expansion
How CanSino Biologics Inc.康希诺生物's international expansion compares to its competitors
CanSino Biologics Inc.康希诺生物YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 CanSino Biologics Inc.康希诺生物You | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Insilico Medicine, backed by Qiming Venture Partners, listed on HKEX as 2025's largest biotech IPO, valued at HK$19.51 billion. The AI-driven drug discovery company aims to extend human healthspan.
Zhou Zhifeng of Qiming Ventures ranked 80th on Forbes 2026 Midas List, first Chinese tech/AI investor on list. His portfolio includes Biren, Zhipu, and other AI companies.
Alex Zhou, Managing Partner at Qiming Venture Partners, debuts at No. 80 on Forbes 2026 Midas List, recognized for his AI and technology investments with four portfolio IPOs in 2026.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about CanSino Biologics Inc.康希诺生物's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
